AJOONI - Ajooni Biotech
📢 Recent Corporate Announcements
Ajooni Biotech has secured its largest-ever single order worth ₹47.52 crores for cattle feed from an existing customer, representing a significant portion of its current revenue. The company also announced the commissioning of its new Khanna plant, which increases total annual production capacity from 60,000 MT to 180,000 MT. For 9M FY26, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Furthermore, the board is evaluating a potential merger with Healthy Biosciences Limited to drive inorganic growth.
- Received record-breaking order worth ₹47.52 crores for scientifically formulated cattle feed
- Commissioned new facility in Khanna, Punjab, tripling total annual capacity to 1,80,000 MT
- Reported 9M FY26 financial performance with ₹122.87 crore revenue and ₹3.37 crore PAT
- Board is actively discussing the merger/amalgamation of Healthy Biosciences Limited with Ajooni
- New plant technology expected to significantly reduce production costs and improve margins
Ajooni Biotech has secured its largest-ever order valued at ₹47.52 crores from an existing client for cattle feed supply. This milestone coincides with the commissioning of a new plant in Khanna, Punjab, which triples the company's total annual production capacity to 1,80,000 MT. For the 9M FY26 period, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Additionally, the board is exploring a strategic merger with Healthy Biosciences Limited to further consolidate its market presence.
- Secured the biggest-ever order in company history worth ₹47.52 crores.
- Commissioned a new 1,20,000 MT plant, taking total capacity to 1,80,000 MT per year.
- Reported 9M FY26 total revenue of ₹122.87 crores and PAT of ₹3.37 crores.
- Board is currently evaluating a merger proposal with Healthy Biosciences Limited.
Ajooni Biotech Limited has successfully secured a significant order valued at Rs. 47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the company's strengthening market position in the animal nutrition segment. The contract underscores growing demand and customer confidence in the company's product quality. This development is expected to provide a substantial boost to the company's revenue and operational scale in the near term.
- Received a new supply order worth Rs. 47.52 crores.
- Order pertains to the supply of scientifically formulated cattle feed.
- Strengthens the company's footprint in the animal nutrition industry.
- Reflects robust demand and customer trust in product excellence.
Ajooni Biotech Limited has announced the receipt of a substantial order valued at ₹47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the growing demand for the company's animal nutrition products and strengthens its market position. The contract represents a significant milestone in the company's growth journey and reflects strong customer confidence in its product quality. This development is expected to contribute positively to the company's revenue and operational scale.
- Secured a major order worth ₹47.52 crores for cattle feed supply
- Reinforces the company's presence in the specialized animal nutrition segment
- Demonstrates strong customer trust and demand for scientifically formulated products
- Significant milestone expected to drive future revenue growth
Ajooni Biotech reported a strong financial performance for the quarter ended December 31, 2025, with revenue from operations growing 72.6% YoY to ₹58.75 crore. Net profit for the quarter surged by 125.7% YoY to ₹1.65 crore, up from ₹0.73 crore in the same period last year. For the nine-month period, the company has already matched its previous full-year profit, reaching ₹3.37 crore. While the board discussed a merger with Healthy Biosciences Limited, the decision has been deferred for further evaluation, which remains a key watchpoint for future growth.
- Revenue from operations grew 72.6% YoY to ₹5,875.33 Lakhs in Q3 FY26.
- Net profit for the quarter increased 125.7% YoY to ₹164.80 Lakhs.
- 9-month (Apr-Dec 2025) revenue reached ₹12,175.61 Lakhs vs ₹8,541.75 Lakhs YoY.
- Earnings Per Share (EPS) for the quarter improved to ₹0.10 from ₹0.04 YoY.
- Board deferred the merger proposal of Healthy Biosciences Limited pending further internal evaluation.
Ajooni Biotech Limited has officially notified the National Stock Exchange regarding the functionality of its corporate website. The company confirms that its website is fully updated in accordance with Regulation 46 of SEBI (LODR) Regulations, 2015. This filing ensures that all mandatory disclosures and investor information are accessible to the public. While this is a procedural compliance matter, it reflects the company's adherence to regulatory transparency standards.
- Company confirms website www.ajoonibiotech.com is fully functional
- Compliance achieved under Regulation 46 of SEBI (LODR) Regulations, 2015
- Official notification submitted to the National Stock Exchange on January 07, 2026
Ajooni Biotech Limited has submitted a formal undertaking to the National Stock Exchange confirming that its corporate website is fully updated and functional. This filing is in adherence to Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement, dated January 07, 2026, ensures that the company remains compliant with mandatory disclosure norms. This is a standard administrative procedure and does not reflect any change in the company's financial or operational status.
- Formal undertaking submitted to NSE on January 07, 2026, regarding website functionality.
- Compliance confirmed under Regulation 46 of SEBI (LODR) Regulations, 2015.
- Official website www.ajoonibiotech.com is verified as updated for investor access to corporate information.
Ajooni Biotech Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This closure is a mandatory compliance step under SEBI (Prohibition of Insider Trading) Regulations, 2015, preceding the declaration of un-audited financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially disclosed to the stock exchange. This is a standard procedure to prevent insider trading during the sensitive period before earnings reports.
- Trading window closure begins on January 1, 2026, for Q3 FY2025-26 financial results.
- Closure applies to all officers, directors, and designated employees of Ajooni Biotech.
- The window will reopen 48 hours after the announcement of the un-audited financial results to the exchange.
- The filing is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Ajooni Biotech Limited has announced the commencement of commercial production at its newly installed manufacturing facilities in Khanna, Punjab. This expansion is expected to significantly contribute to the company's revenue and market presence. Furthermore, the company has secured new orders for cattle feed valued at ₹27 Crores, demonstrating strong customer trust in both domestic and export markets. Investors should monitor the impact of this increased production capacity and order fulfillment on the company's future financial performance.
- Commercial production commenced at newly installed manufacturing facilities.
- Received new orders for cattle feed valued at ₹27 Crores.
- New facility located in Khanna, Punjab.
Financial Performance
Revenue Growth by Segment
Standalone revenue from operations for H1 FY26 (ended September 30, 2025) was INR 63.00 Cr, representing a 22.6% growth compared to INR 51.38 Cr in H1 FY25. The company operates in a single business segment (animal feed), making segment-wise growth identical to overall growth.
Geographic Revenue Split
Not explicitly disclosed in percentages, but operations and manufacturing facilities are concentrated in Punjab (Mohali and Khanna), serving the regional livestock market.
Profitability Margins
Profit Before Tax (PBT) for H1 FY26 was INR 2.26 Cr, a margin of 3.59%. Operating margins have historically been volatile between 3-4% due to raw material price fluctuations but are projected to improve to 4.5-6.0% over the medium term as high-margin products scale.
EBITDA Margin
Operating margin was reported at 1.06% for the first nine months of FY24, significantly impacted by an inventory loss of INR 1.9 Cr due to floods. Normalised margins are expected to recover to 3.5-4.0% for the full fiscal year.
Capital Expenditure
The company is executing a capital expenditure plan of INR 16.5 Cr for a new factory to enhance production capacity, which is expected to be operational by April 2025.
Credit Rating & Borrowing
CRISIL upgraded the company's rating to 'CRISIL BB+/Stable' from 'CRISIL BB/Stable'. The capital structure is supported by low gearing of 0.09x and an interest coverage ratio of approximately 7 times.
Operational Drivers
Raw Materials
Key raw materials include de-oiled rice bran, maize, bran, and mustard. Cost of materials consumed in H1 FY26 was INR 50.57 Cr, accounting for 80.3% of total revenue.
Import Sources
Raw materials are primarily sourced from domestic agricultural markets in Northern India, specifically Punjab and surrounding states.
Capacity Expansion
Current capacity is being expanded with a new factory (INR 16.5 Cr capex) slated for completion by April 2025 to meet growing demand for compound animal feed.
Raw Material Costs
Raw material costs grew 12.5% YoY in H1 FY26 to INR 50.57 Cr. Procurement strategies focus on cost efficiency methods to mitigate the impact of high fragmentation in the supplier market.
Manufacturing Efficiency
The company is focusing on incremental sales of feed supplements which provide higher margins of 9-10% compared to standard cattle feed.
Logistics & Distribution
Distribution is managed from the central works in Khanna, Punjab, primarily targeting the regional dairy and livestock industry.
Strategic Growth
Expected Growth Rate
25-30%
Growth Strategy
Growth will be driven by a rights share issue of INR 40 Cr in FY25 to strengthen net worth to INR 84 Cr, capacity enhancement via a new INR 16.5 Cr factory, and a strategic shift toward high-margin (9-10%) feed supplements.
Products & Services
Compound animal feed including cattle feed, cattle feed chips, camel feed, cotton oil cake, mustard oil cake, and specialized feed supplements.
Brand Portfolio
AJOONI
New Products/Services
Expansion into specialized feed supplements is expected to contribute significantly to the medium-term margin target of 4.5-6.0%.
Market Expansion
Targeting increased market share in the animal healthcare and nutrition space through the new production facility operational by Q1 FY26.
External Factors
Industry Trends
The industry is shifting toward compound feed and nutritional supplements to improve livestock yield. The company is positioning itself to capture this 9-10% margin segment.
Competitive Landscape
The market is highly fragmented with many small-scale unorganized players, leading to intense price competition.
Competitive Moat
The moat is built on the extensive experience of promoter Mr. Jasjot Singh and established customer relationships, supported by a very low-debt financial profile (0.09x gearing).
Macro Economic Sensitivity
Highly sensitive to agricultural commodity inflation and monsoon patterns affecting raw material availability and pricing.
Consumer Behavior
Increasing awareness among dairy farmers regarding the benefits of balanced nutrition for cattle is driving demand for compound feed over traditional fodder.
Geopolitical Risks
Low direct impact as operations are primarily domestic and focused on the regional agricultural economy.
Regulatory & Governance
Industry Regulations
Operations are governed by the Companies Act 2013 and agricultural manufacturing standards. The company maintains proper board processes and compliance mechanisms.
Environmental Compliance
The company maintains compliance with applicable statutory provisions; no specific ESG cost values were disclosed.
Taxation Policy Impact
Current tax liabilities were INR 0.32 Cr as of September 30, 2025.
Legal Contingencies
No major pending court cases or case values were disclosed. Minor procedural delays were noted in SEBI filings, such as a 48-hour delay in publishing Q1 FY25 results.
Risk Analysis
Key Uncertainties
Volatility in raw material prices (maize, mustard) and potential for environmental disruptions (floods) represent the primary business risks with a potential 2-3% impact on margins.
Geographic Concentration Risk
High concentration in Punjab, with 100% of manufacturing and the majority of revenue derived from the Northern Indian region.
Third Party Dependencies
Dependency on agricultural commodity suppliers; however, no single supplier dependency was highlighted as a critical risk.
Technology Obsolescence Risk
Low risk given the nature of the animal feed industry, though the company is adopting cost-efficiency technologies in its new factory.
Credit & Counterparty Risk
Receivables decreased by INR 0.40 Cr in H1 FY26, indicating stable collection cycles and healthy counterparty credit quality.